^
    Back
    Association details:
    Biomarker:MSH2 mutation + MSH6 mutation + BRCA1 mutation
    Cancer:Prostate Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    AACR 2021
    Title:

    LB004 - Nivolumab (NIVO) and ipilimumab (IPI) treatment in prostate cancer with an immunogenic signature: cohort 1 of the NEPTUNES multi-centre, two-stage biomarker-selected Phase II trial

    Published date:
    04/09/2021
    Excerpt:
    Pts with mCRPC who progressed following ≥1 line of therapy and ImS+ were eligible. ImS+ was defined by ≥1 of the following: 1) mismatch repair deficient (MMRD) by immunohistochemistry (IHC); 2) DNA damage repair deficient (DDRD) excluding MMRD, detected by the UW-OncoPlex targeted exome sequencing assay...The overall CRR was 9/35 (26%, 95%CI 12-43%).... NIVO + IPI demonstrated significant activity in biomarker selected, pre-treated pts with mCRPC.